Homocysteine: update on a new risk factor

Cleve Clin J Med. 1997 Nov-Dec;64(10):543-9. doi: 10.3949/ccjm.64.10.543.

Abstract

A high fasting plasma homocysteine level is an independent risk factor for atherosclerosis and venous thrombosis. Vitamin therapy can lower homocysteine levels, but no benefit has yet been demonstrated; studies using clinical outcomes as endpoints are now in progress.

Publication types

  • Review

MeSH terms

  • Arteriosclerosis / epidemiology
  • Arteriosclerosis / etiology*
  • Arteriosclerosis / therapy
  • Folic Acid / therapeutic use
  • Homocysteine / biosynthesis
  • Homocysteine / blood*
  • Humans
  • Prognosis
  • Pyridoxine / therapeutic use
  • Risk Factors
  • Thrombophlebitis / epidemiology
  • Thrombophlebitis / etiology*
  • Thrombophlebitis / therapy
  • Vitamin B 12 / therapeutic use

Substances

  • Homocysteine
  • Folic Acid
  • Pyridoxine
  • Vitamin B 12